Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
暂无分享,去创建一个
Y Z Xu | V. Heinemann | L. Hertel | W. Plunkett | G. Grindey | Volker Heinemann | G B Grindey | W Plunkett | V Heinemann | S Chubb | A Sen | L W Hertel | Y. Z. Xu | S. Chubb | A. Sen | G. B. Grindey | Alina Sen | YÂ ¡-ZhengXu
[1] J. A. Fyfe,et al. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. , 1989, Analytical biochemistry.
[2] D. Hoard,et al. CONVERSION OF MONO- AND OLIGODEOXYRIBONUCLEOTIDES TO 5-TRIPHOSPHATES. , 1965, Journal of the American Chemical Society.
[3] L. Hertel,et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.
[4] W. Plunkett,et al. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. , 1990, Cancer research.
[5] H. Kantarjian,et al. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. , 1990, Cancer research.
[6] B. Mitchell,et al. Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. , 1989, The Journal of biological chemistry.
[7] L. Hertel,et al. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides , 1988 .
[8] L. Hertel,et al. Synthesis of 2-Deoxy-2,2-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl Nucleosides. , 1988 .
[9] E. Estey,et al. Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.
[10] G. Maley,et al. The Regulatory Influence of Allosteric Effectors on Deoxycytidylate Deaminases , 1972 .
[11] J. Bollinger,et al. 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. , 1991, Journal of medicinal chemistry.
[12] V. Heinemann,et al. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. , 1989, Biochemical pharmacology.
[13] G. Maley,et al. Tetrahydrodeoxyuridylate: a potent inhibitor of deoxycytidylate deaminase. , 1971, Archives of biochemistry and biophysics.
[14] R D Brown,et al. ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. , 1978, Journal of pharmaceutical sciences.
[15] D. Ives,et al. Human deoxycytidine kinase: kinetic mechanism and end product regulation. , 1989, Biochemistry.
[16] L. Hertel,et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.
[17] M. Rossi,et al. Studies on analogs of isosteric and allosteric ligands of deoxycytidylate aminohydrolase. , 1970, Biochemistry.
[18] G. Snow,et al. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. , 1991, Cancer research.
[19] A. Fridland,et al. Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. , 1987, Seminars in oncology.
[20] V. Heinemann,et al. 2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells , 1989 .
[21] Y Z Xu,et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.
[22] V. Heinemann,et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.
[23] S. Mineishi,et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.